Company Contents
Quick Facts & Snapshot
Summary
The Arbovirus Testing market is entering a disciplined growth phase, driven by rising outbreak surveillance, travel screening, and blood-safety regulations. Leading diagnostics vendors are consolidating share through molecular platforms, syndromic panels, and rapid tests. From US$ 1.30 Billion in 2025, the market is projected to reach US$ 2.07 Billion by 2032, reflecting a robust 6.80% CAGR.
Source: Secondary Information and ReportMines Research Team - 2026
Ranking Methodology
Rankings for leading Arbovirus Testing market companies are based on a composite scoring model that blends quantitative and qualitative metrics. Core quantitative inputs include 2025 arbovirus-related diagnostics revenue, multi-year growth trajectories, win rates in public health and reference-lab tenders, and size of installed PCR and immunoassay analyzers. Qualitative factors cover portfolio breadth across molecular, serology, and rapid tests, technology differentiation such as multiplex syndromic panels and automation, regulatory footprint, global distribution reach, and aftersales and training capabilities. Additional weighting is assigned to R&D intensity, pipeline robustness, and ability to support multi-year surveillance or screening contracts with ministries of health, blood banks, and hospital networks. Each company receives sub-scores by dimension, normalized to a 100-point scale, which are then aggregated to derive final rankings, ensuring an objective, evidence-based view of competitive positioning.
Top 10 Companies in Arbovirus Testing
Source: Secondary Information and ReportMines Research Team - 2026
Detailed Company Profiles
Roche Diagnostics
Roche Diagnostics is a global diagnostics leader with strong molecular platforms and blood-screening solutions for high-volume arbovirus surveillance programs.
Abbott Laboratories
Abbott Laboratories combines molecular systems and point-of-care devices to provide comprehensive arbovirus testing across central labs and decentralized settings.
Thermo Fisher Scientific
Thermo Fisher Scientific supplies advanced qPCR and sequencing solutions that underpin arbovirus surveillance in public health and research settings worldwide.
Siemens Healthineers
Siemens Healthineers focuses on automated immunoassay platforms offering high-throughput arbovirus serology for hospitals and regional laboratories.
bioMérieux
bioMérieux specializes in syndromic molecular diagnostics, providing multiplex panels that cover arboviruses within broader febrile-illness testing strategies.
DiaSorin S.p.A.
DiaSorin focuses on specialty serology and molecular assays, addressing arbovirus diagnostics through its LIAISON and Simplexa platforms.
QuidelOrtho Corporation
QuidelOrtho delivers rapid tests and immunoassay solutions that enable decentralized arbovirus screening in clinics and laboratories.
Becton, Dickinson and Company (BD)
BD leverages its molecular systems and sample-collection products to support integrated arbovirus testing workflows for laboratories.
Hologic, Inc.
Hologic offers high-throughput molecular platforms used for arbovirus screening, particularly in blood and plasma applications.
GenMark Diagnostics (a Roche company)
GenMark Diagnostics develops syndromic ePlex panels that integrate arboviruses into comprehensive infectious-disease testing strategies.
SWOT Leaders
Roche Diagnostics
SWOT Snapshot
Large installed base in blood screening and molecular platforms, strong regulatory track record, and comprehensive service infrastructure.
High capital expenditure requirements and complex implementation may slow adoption in resource-limited laboratories.
Expansion of mandatory arbovirus screening in blood centers and integration of emerging viruses into multiplex panels.
Intensifying competition from cost-efficient regional players and potential pricing pressure from large tenders.
Abbott Laboratories
SWOT Snapshot
Balanced portfolio across molecular, serology, and POC, with strong presence in endemic geographies and travel medicine channels.
Exposure to reimbursement constraints and procurement cycles in several key public health markets.
Rising demand for rapid and near-patient testing in clinics, airports, occupational health, and blood donation centers.
New low-cost rapid test entrants and evolving regulatory scrutiny on rapid assay performance claims.
Thermo Fisher Scientific
SWOT Snapshot
Deep R&D capabilities, strong presence in public health and research labs, and broad portfolio spanning qPCR and NGS.
More limited routine clinical menu compared with full-spectrum IVD competitors, especially in smaller hospitals.
Scaling genomic surveillance initiatives and supplying OEM reagents for emerging Arbovirus Testing market companies.
Budget constraints in public health and research funding cycles and competition from other sequencing platform providers.
Arbovirus Testing Market Regional Competitive Landscape
North America remains the largest revenue contributor, driven by robust blood-screening mandates, established surveillance programs, and high testing throughput. Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific anchor the landscape, while QuidelOrtho and BD supply rapid and syndromic solutions. Investments focus on West Nile virus, emerging arboviruses, and integrated vector-borne disease panels.
In Latin America, arbovirus burden from dengue, Zika, and chikungunya creates strong demand for affordable, scalable diagnostics. Abbott, bioMérieux, and Roche hold significant shares through blood-screening and hospital contracts. Rapid tests from QuidelOrtho complement central-lab systems. Public tenders, Pan American Health Organization initiatives, and donor-supported programs shape competitive dynamics and pricing.
Europe shows balanced demand across molecular, serology, and research-use assays, with emphasis on West Nile virus and imported tropical infections. Siemens Healthineers, DiaSorin, Roche Diagnostics, and bioMérieux are leading Arbovirus Testing market companies. Public health institutes increasingly procure multiplex PCR and NGS-based surveillance solutions from Thermo Fisher and GenMark Diagnostics.
Asia Pacific is the fastest-growing region, underpinned by recurring dengue outbreaks, urbanization, and expanding private laboratory chains. Abbott and Roche scale molecular platforms, while QuidelOrtho and regional challengers supply cost-sensitive rapid tests. Governments in Southeast Asia invest in surveillance networks, stimulating demand for syndromic panels from bioMérieux and research tools from Thermo Fisher.
The Middle East and Africa region is characterized by uneven diagnostics infrastructure, with reference laboratories and select private chains leading adoption of advanced systems. Siemens Healthineers and Roche Diagnostics dominate central-lab installations, while BD and Abbott supply molecular and POC solutions. International funding, outbreak-response projects, and mobile clinics are critical channels for Arbovirus Testing market companies.
In emerging Eastern Europe and Central Asia, vector expansion and climate change are raising arbovirus awareness. Testing volumes remain moderate but are growing, favoring mid-throughput analyzers and versatile immunoassay platforms from Siemens Healthineers and DiaSorin. Partnerships with public health agencies and regional distributors are central to expansion strategies for established Arbovirus Testing market companies.
Challengers & Emerging Players
Emerging Challengers & Disruptive Start-Ups
Develops low-cost multiplex PCR panels optimized for dengue, Zika, and chikungunya, targeting regional public labs with minimal-infrastructure workflows.
Offers AI-assisted lateral flow readers and smartphone connectivity for quantitative dengue and chikungunya testing in peri-urban and rural settings.
Provides cloud-native analytics that aggregates arbovirus test results across labs to support real-time outbreak intelligence dashboards for health authorities.
Combines microfluidic cartridges and portable PCR devices to deliver near-patient arbovirus testing for airports, seaports, and field surveillance teams.
Focuses on advanced serology panels with differential markers that distinguish primary from secondary dengue infections for risk stratification.
Builds modular lab-in-a-box platforms for integrated arbovirus PCR, serology, and connectivity tailored to under-resourced African laboratory networks.
Arbovirus Testing Market Future Outlook & Key Success Factors (2026-2032)
From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Arbovirus Testing market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.
Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Arbovirus Testingmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.
Frequently Asked Questions
Find answers to common questions about this company report.